Old drugs need 'repurposing' for new uses, physician says

Overly restrictive intellectual property laws devalue the "repurposing" of existing medications for new uses, slowing their availability as life-saving treatments, a Portland researcher contends.

S. Paul Berger, M.D., assistant professor of psychiatry and behavioral neuroscience in the Oregon Health & Science University School of Medicine and the Portland Veterans Affairs Medical Center, writes in a letter appearing in the current issue of the journal Nature that "economics and patent laws" keep pharmaceutical companies from finding new uses for old drugs.

Instead, drug companies "reinvent the wheel" by spending millions of dollars to develop new drugs for diseases that existing drugs have already been shown to be effective against in off-label uses, Berger believes. As a result, new drugs take years to reach consumers who need them as they undergo lengthy testing in clinical trials required by the Food and Drug Administration, and the development costs are passed on to consumers.

In his Nature letter, Berger cites recent comments by Federick Goodwin, M.D., former director of the National Institute of Mental Health, who said lithium remains underused in high-risk patients, despite strong evidence that, unlike most other psychiatric medications, it significantly lowers the risk of suicide in people with manic-depressive illness.

"Similarly," Berger writes, "although folic acid has been shown to increase the efficacy of antipsychotic medications in certain patients, a psychiatrist at a recent meeting told me that he could not persuade his colleagues to prescribe this comparatively harmless vitamin."

Berger suggests that such difficulties "stem from the failure of intellectual property laws to assign sufficient value to ‘use’ patents, involving new uses for old medications. In effect, a discovery of immense human value — preventing suicide — is assigned a negligible economic value that fails to motivate the pharmaceutical industry to develop the drug."

He adds that the "antiquated laws governing new uses for existing medications need to be reformed if lifesaving discoveries are to be exploited."

To prove his point, Berger is about to publish two papers demonstrating new uses for old drugs. One points to an "alpha-1 antagonist" that's been used to treat sleep disturbances and nightmares of post-traumatic stress disorder, but which shows promise in preventing brain damage caused by traumatic stress sufficient to precipitate PTSD or relapse of schizophrenia and depression. The other is a "sigma-1 antagonist" once tested as a schizophrenia treatment, but which has been found to suppress the involuntary "dyskinetic" (abrupt and awkward) movements that are disabling side effects of taking levodopa for Parkinson's disease over long periods.

But Berger acknowledges that getting drug companies to pick up these new uses for old medications is an uphill battle.

"There are so many off-label uses for medications that people come up with, but the drug companies have no financial incentives to develop generic drugs for new indications. There's no money in it," Berger said.

Such attitudes are creating a logjam in the movement of discoveries from the laboratory to the clinic, he added. "Extrapolating from bench progress, the pharmaceutical industry should be growing the way the computer industry did in the 1980s, fueling an economic boom. The number of new drugs for my veteran patients with psychiatric illnesses from Iraq or earlier conflicts is much less than I expected and declining at a time where it should be increasing."

Source: Oregon Health & Science University

Related stories:

Aspirin in Heart Attack Prevention: How Much, How Long?
A low dose of aspirin appears to be just as effective as a higher dose in preventing a heart attack, stroke or death among patients with stable cardiovascular disease, say researchers at Duke University Medical Center.
Brain-nourishing molecule may predict schizophrenia relapse
A factor that helps optimize brain formation and function may also provide clues about whether patients suffering with schizophrenia are headed toward relapse, researchers say.
Had an angioplasty? Maybe it wasn't needed
Most elective angioplasties, including those in Wisconsin, are done without checking to see whether they are needed by doing a non-invasive stress test, an analysis has found.
Statins may prevent miscarriages
Hospital for Special Surgery researchers have found that statins may be able to prevent miscarriages in women who are suffering from pregnancy complications caused by antiphospholipid syndrome (APS), according to a study in mice. In this autoimmune syndrome, the body produces antibodies directed at phospholipids, the main components of cell membranes. This news comes from a study published in the October issue of the Journal of Clinical Investigation that is currently online in advance of print.
Researchers explore marijuana and mental health
(PhysOrg.com) -- A team of mental health experts from the University of Western Sydney say young people who have developed a dependence on cannabis are likely to continue using the drug following the diagnosis of a mental illness.
Learning how not to be afraid
Why do some people have the ability to remain calm and relaxed even in the most stressful situations? New experiments in mice by Howard Hughes Medical Institute (HHMI) researchers are providing insight into how the brain changes when the animals learn to feel safe and secure in situations that would normally make them anxious.
Study suggests LF elimination program is 'best buy in public health'
A study published today concludes that in the ten years since its initiation, the international effort to eliminate lymphatic filariasis (LF) has made a large impact towards ridding the world of one of its most debilitating diseases. The analysis found that the LF elimination programme has prevented 6.6 million children from acquiring LF and stopped another 9.5 million people already infected with the disease from progressing to more debilitating stages. These efforts are the result of the most rapid scale-up of a drug administration programme in public health history, delivering what the study calls a "best buy in public health".
Scientists go chatting to hear kids' drug concerns
(AP) -- It's nothing to LOL about. Students these days often have ready access to marijuana, alcohol and tobacco but they don't feel comfortable talking about the ramifications. So, some of the nation's government scientists went to the computer chat room Tuesday to make it a little easier for them.

News discussion:

Medicine & Health news